Get our newsletter delivered directly to your inbox
I have already subscribed | Do not show this message again
Boletines
Your email has been successfully registered.
Cuba was represented by Cimab S.A. and Mexico by Neuronic Mexicana S.A. de C.V. The venture has an exclusive license for the development of biotechnological products, including NeuroEPO, which is "an intranasal formulation of recombinant human erythropoietin with a low sialic acid content, currently under clinical evaluation."
Cuba and Mexico settled on Tuesday the joint venture IncuBio in the Mariel Special Development Zone which aims to finance "proof-of-concept clinical trials in developed country markets."
Cuba was represented by Cimab S.A. and Mexico by Neuronic Mexicana S.A. de C.V. The venture has an exclusive license for the development of biotechnological products, including NeuroEPO, which is "an intranasal formulation of recombinant human erythropoietin with a low sialic acid content, currently under clinical evaluation."
Constituyen nueva empresa mixta en la Zona Especial de Desarrollo Mariel https://t.co/XDY7L2LJLc
NeuroEPO is one of the most promising products in the portfolio of the Cuban Center for Molecular Immunology (CIM). During the latest proof-of-concept trial in Cuba, NeuroEPO acted as "a homeostatic regulator of the brain and improvement of cognitive deterioration in Alzheimer's patients," a report by Prensa Latina.
Moreover, by joining the venture, the Cuban company Cimab S.A. adds its fifth asset, since it is already a shareholder of other joint ventures in China, Taiwan, and Singapore.
#FromTheSouth News Bits | The people and government of Cuba pay tribute to the historical leader of the Cuban Revolution, Commander Fidel Castro on the 95th anniversary of his birth. pic.twitter.com/ussJrfKyxt